BTK-话题@MedSci

#BTK#

73篇内容 | 2419人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1539092, encodeId=c8da153909221, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=徐卫教授：泽布替尼在复发/难治CLL中疗效及安全性均优，有望成为“Best in-class”BTK抑制剂, objectType=article, longId=174323, objectId=556a1e4323e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556a1e4323e6, replyNumber=0, likeNumber=82, createdTime=2019-06-29, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556a1e4323e6, moduleTitle=徐卫教授：泽布替尼在复发/难治CLL中疗效及安全性均优，有望成为“Best in-class”BTK抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556a1e4323e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539091, encodeId=0d0415390910d, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=NEJM：口服BTK抑制剂治疗多发性硬化, objectType=article, longId=168870, objectId=9b371688e02f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b371688e02f, replyNumber=0, likeNumber=114, createdTime=2019-06-22, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b371688e02f, moduleTitle=NEJM：口服BTK抑制剂治疗多发性硬化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b371688e02f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539090, encodeId=cb981539090cc, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期, objectType=article, longId=168704, objectId=32eb168e0473, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32eb168e0473, replyNumber=0, likeNumber=60, createdTime=2019-06-20, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32eb168e0473, moduleTitle=BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32eb168e0473)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539089, encodeId=8b94153908954, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, objectType=article, longId=168695, objectId=da9416869531, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9416869531, replyNumber=0, likeNumber=71, createdTime=2019-06-20, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9416869531, moduleTitle=2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9416869531)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539088, encodeId=822d153908813, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据, objectType=article, longId=168608, objectId=f819168608ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f819168608ec, replyNumber=0, likeNumber=77, createdTime=2019-06-18, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f819168608ec, moduleTitle=第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f819168608ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539087, encodeId=49d9153908ee0, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂ARQ 531的I期试验数据, objectType=article, longId=168606, objectId=a3671686067b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3671686067b, replyNumber=0, likeNumber=64, createdTime=2019-06-18, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3671686067b, moduleTitle=BTK抑制剂ARQ 531的I期试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3671686067b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539086, encodeId=95e2153908645, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破, objectType=article, longId=167336, objectId=20e616e33681, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20e616e33681, replyNumber=0, likeNumber=77, createdTime=2019-06-02, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20e616e33681, moduleTitle=新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20e616e33681)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539085, encodeId=7203153908578, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, objectType=article, longId=165920, objectId=671e16592080, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=671e16592080, replyNumber=0, likeNumber=0, createdTime=2019-05-14, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=671e16592080, moduleTitle=AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=671e16592080)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539084, encodeId=3552153908480, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, objectType=article, longId=158889, objectId=58081588897d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58081588897d, replyNumber=0, likeNumber=0, createdTime=2019-01-27, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58081588897d, moduleTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58081588897d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539083, encodeId=81b41539083b4, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, objectType=article, longId=157519, objectId=39d615e51935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d615e51935, replyNumber=0, likeNumber=29, createdTime=2019-01-09, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d615e51935, moduleTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d615e51935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539082, encodeId=5f92153908240, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, objectType=article, longId=157138, objectId=55df15e138c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55df15e138c5, replyNumber=0, likeNumber=53, createdTime=2019-01-02, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55df15e138c5, moduleTitle=李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55df15e138c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539081, encodeId=e7351539081ac, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=淋巴瘤治疗：弯道超车的新一代BTK抑制剂到底好在哪？, objectType=article, longId=155355, objectId=117d155355bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117d155355bd, replyNumber=0, likeNumber=62, createdTime=2018-12-09, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117d155355bd, moduleTitle=淋巴瘤治疗：弯道超车的新一代BTK抑制剂到底好在哪？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117d155355bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539080, encodeId=f900153908028, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=新一代BTK抑制剂Zanubrutinib具有多重优势, objectType=article, longId=154851, objectId=cf8715485131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf8715485131, replyNumber=0, likeNumber=73, createdTime=2018-12-02, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf8715485131, moduleTitle=新一代BTK抑制剂Zanubrutinib具有多重优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf8715485131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539079, encodeId=ad5b15390e9e8, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, objectType=article, longId=154710, objectId=3672154e10c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3672154e10c1, replyNumber=0, likeNumber=40, createdTime=2018-12-01, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3672154e10c1, moduleTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3672154e10c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539078, encodeId=673015390e863, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势, objectType=article, longId=154636, objectId=cc21154636ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc21154636ff, replyNumber=0, likeNumber=79, createdTime=2018-12-01, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc21154636ff, moduleTitle=朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc21154636ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539077, encodeId=2e3d15390e70e, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天, objectType=article, longId=152201, objectId=c131152201af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c131152201af, replyNumber=0, likeNumber=62, createdTime=2018-10-31, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c131152201af, moduleTitle=【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c131152201af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539076, encodeId=d47d15390e634, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=欧洲血液学杂志：TEC与BTK抑制剂出血副作用无关, objectType=article, longId=151581, objectId=71af15158109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71af15158109, replyNumber=0, likeNumber=67, createdTime=2018-10-24, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71af15158109, moduleTitle=欧洲血液学杂志：TEC与BTK抑制剂出血副作用无关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71af15158109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539075, encodeId=3d1f15390e579, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性, objectType=article, longId=149438, objectId=e16114943801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e16114943801, replyNumber=0, likeNumber=128, createdTime=2018-09-25, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e16114943801, moduleTitle=CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e16114943801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539074, encodeId=b98715390e431, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=【2018年EHA抢鲜报道】BTK抑制剂可阻断 MCL细胞与单核巨噬细胞之间的相关作用, objectType=article, longId=140719, objectId=96d1140e197c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96d1140e197c, replyNumber=0, likeNumber=30, createdTime=2018-06-15, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96d1140e197c, moduleTitle=【2018年EHA抢鲜报道】BTK抑制剂可阻断 MCL细胞与单核巨噬细胞之间的相关作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96d1140e197c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1539073, encodeId=4f3115390e3ae, content=<a href='/topic/show?id=6bce3e7106' target=_blank style='color:#2F92EE;'>#BTK#</a>, objectTitle=Blood：BTKCys481Ser突变通过再激活ERK1/2驱动恶性B细胞产生依鲁替尼耐药性，并通过旁分泌对未突变细胞产生保护作用, objectType=article, longId=131375, objectId=baed1313e5b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baed1313e5b2, replyNumber=0, likeNumber=53, createdTime=2018-03-05, rootId=0, userName=fengting7, userId=61d813108447, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baed1313e5b2, moduleTitle=Blood：BTKCys481Ser突变通过再激活ERK1/2驱动恶性B细胞产生依鲁替尼耐药性，并通过旁分泌对未突变细胞产生保护作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baed1313e5b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BTK

2020-05-29

fengting7 (审核中...)

前往app查看评论内容

#BTK#

徐卫教授：泽布替尼在复发/难治CLL中疗效及安全性均优，有望成为“Best in-class”BTK抑制剂

2019-06-29

fengting7 (审核中...)

前往app查看评论内容

#BTK#

NEJM：口服BTK抑制剂治疗多发性硬化

2019-06-22

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂Acalabrutinib显著延长R/R CLL的无疾病进展生存期

2019-06-20

fengting7 (审核中...)

前往app查看评论内容

#BTK#

2019 EHA：AZ的BTK抑制剂Calquence显着延长慢性淋巴细胞白血病患者的无进展生存期

2019-06-20

fengting7 (审核中...)

前往app查看评论内容

#BTK#

第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据

2019-06-18

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂ARQ 531的I期试验数据

2019-06-18

fengting7 (审核中...)

前往app查看评论内容

#BTK#

新型PD-1抑制剂和BTK抑制剂为淋巴瘤治疗带来新突破

2019-06-02

fengting7 (审核中...)

前往app查看评论内容

#BTK#

AAN：II期临床试验证实口服Bruton酪氨酸激酶（BTK）抑制剂治疗多发性硬化症的有效性

2019-05-14

fengting7 (审核中...)

前往app查看评论内容

#BTK#

BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验

2019-01-27

fengting7 (审核中...)

前往app查看评论内容

#BTK#

专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则

2019-01-09

fengting7 (审核中...)

前往app查看评论内容

#BTK#

李志铭教授：疗效与安全性双赢--新型BTK抑制剂Zanubrutinib为B细胞淋巴瘤患者带来治疗新选择

2019-01-02

fengting7 (审核中...)

前往app查看评论内容

#BTK#

淋巴瘤治疗：弯道超车的新一代BTK抑制剂到底好在哪？

2018-12-09

fengting7 (审核中...)

前往app查看评论内容

#BTK#

新一代BTK抑制剂Zanubrutinib具有多重优势

2018-12-02

fengting7 (审核中...)

前往app查看评论内容

#BTK#

【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点

2018-12-01

fengting7 (审核中...)

前往app查看评论内容

#BTK#

朱军教授：新一代BTK抑制剂Zanubrutinib具有多重优势

2018-12-01

fengting7 (审核中...)

前往app查看评论内容

#BTK#

【2018CSH】赵维莅教授：新一代BTK抑制剂Zanubrutinib的应用体会及前景展望肿瘤资讯昨天

2018-10-31

fengting7 (审核中...)

前往app查看评论内容

#BTK#

欧洲血液学杂志：TEC与BTK抑制剂出血副作用无关

2018-10-24

fengting7 (审核中...)

前往app查看评论内容

#BTK#

CSCO 2018 | 第二代BTK抑制剂Zanubrutinib，持久和特异的靶向亲和力带来更优的疗效和安全性

2018-09-25

fengting7 (审核中...)

前往app查看评论内容

#BTK#

【2018年EHA抢鲜报道】BTK抑制剂可阻断 MCL细胞与单核巨噬细胞之间的相关作用

2018-06-15

fengting7 (审核中...)

前往app查看评论内容

#BTK#

Blood：BTKCys481Ser突变通过再激活ERK1/2驱动恶性B细胞产生依鲁替尼耐药性，并通过旁分泌对未突变细胞产生保护作用

2018-03-05

科室
- - 订阅+
  - 更多科室
工具
服务